A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin
Status:
Completed
Trial end date:
2019-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the influence of repeated oral doses of KW-6356 on
the pharmacokinetics of index substrates for CYP3A4/5, CYP1A2 and BCRP.